Navigation Links
Clear racial discrepancies exist among patients with CKD
Date:5/19/2008

Washington, DC (May 19, 2008) Black patients have a higher risk of dying in the early stages of chronic kidney disease (CKD) than whites, according to a study appearing in the July 2008 issue of the Journal of the American Society Nephrology (JASN). The findings may explain why blacks have better survival rates once they reach advanced stages of the diseasein essence, because only the healthiest blacks are surviving long enough to develop later stages of the disease. If white patients are given better care in managing their condition early on, even less healthy patients may live to develop advanced disease. But, their compromised health may put them at increased risk of death in the long term compared with blacks.

In addition, the studys results indicate that racial differences in the death rates of chronic kidney disease patients depend more on sociological factors than on biological ones. Poverty and lack of education and medical insurance in particular may contribute to the high death rates among black individuals.

Previous research has documented that, in general, mortality rates for black individuals are persistently higher than those for whites. However, among patients with late-stage chronic kidney disease, the trend is reversed and black individuals have a survival advantage over whites. Hispanic patients also seem to have a survival advantage over whites in these situations.

Puzzled by this paradox, Dr. Rajnish Mehrotra of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and colleagues set out to find an explanation. They assessed data from a total of 14,611 patients in the Third National Health and Nutrition Examination Survey (NHANESIII), a population-based survey of community-dwelling individuals.

The investigators found that 2,892 of the individuals in the survey had chronic kidney disease, 1,127 of whom died during follow-up. Among those with early-stage disease who were younger than 65 years, blacks had a 78% higher risk of death compared with whites. This elevated risk was significantly related to socioeconomic status and access-to-care. There was also a nonsignificant trend for higher mortality among Hispanics compared with whites.

Dr. Mehrotra and his team conclude that their findings may explain the lower mortality rates observed among black individuals with advanced kidney disease. Blacks may not be receiving as high a quality of care as whites during the early stages of their disease, so that only healthier blacks are surviving and developing later stages of chronic kidney disease.

These data suggest that factors such as education, poverty, and lower probability of medical insurance may be more important in mediating the high risk for death among younger black individuals than are biologic differences, the authors write. This, in turn, may help in prioritizing interventions aimed at reducing the disparities among younger black individuals with chronic kidney disease.


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Nurses Send Sutter a Clear Message
3. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
4. Medical, technological advances prompt updating of nuclear medicine technologists scope of practice
5. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
6. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
7. Trade-offs reveal no clear favorites in alternative energy market
8. OSF HealthCare Achieves Impressive Tobacco Quit Rates with the Free & Clear(R) Quit For Life(TM) Program
9. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
10. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
11. NDO Receives FDA 510(K) Clearance for Plicator II(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: